Resource
This document discusses the risk of second primary malignancies (SPMs) in patients with multiple myeloma (MM) and the impact of different therapies on SPM development. The risk of SPMs in MM is influenced by both host-related and disease-related factors. Host-related risk factors include older…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Highlights of the 2016 Meeting of the American Society of Hematology
Treatment Advances in Multiple Myeloma: Expert Perspectives on…
Resource
Multiple myeloma (MM) is a plasma cell neoplasm with significant molecular heterogeneity. Gene expression profiling (GEP) has contributed significantly to our understanding of the underlying biology and has led to several prognostic gene signatures. However, the best way to apply these GEP…
Resource
On December 2, 2016, 7 members of the International Myeloma Foundation (IMF) Nurse Leadership Board convened in San Diego, California, in concurrence with the American Society of Hematology (ASH) Annual Meeting, to discuss the following topics as they relate to the current therapeutic landscape and…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
The International Myeloma Working Group Establishes Updated Guidelines for Disease Assessment
Fifth Annual…
Resource
The updated criteria for the diagnosis of myeloma represent a paradigm shift in the approach to myeloma and have considerable impact on the management of the disease.
For decades the diagnosis of multiple myeloma required the presence of end-organ damage known as the CRAB criteria, including…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Myeloma Experts of the IMWG Tackle Soaring Costs of Care
The Most Important Questions Facing Myeloma Experts in 2016
ASCO…
Resource
The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
IMF Funds First Large-Scale Screening to Identify and Treat Precursor of Blood Cancer before Disease Develops
Promising 2016…
Resource
Published in the Journal of the Advanced Practitioner in Oncology (JADPRO), this guide is a continuing education activity for health-care professionals. It provides the latest scientific information on effectively managing the care of multiple myeloma patients.
Resource
The IMWG recommendations and information on the diagnosis and management of multiple myeloma-related renal impairment. It discusses the effectiveness and dose modifications of various drugs, including CC, high-dose corticosteroids, thalidomide, and lenalidomide, in improving renal function. The…
Resource
Dear Reader>
A message from IMF President Susie Novis
Scientific & Clinical
Highlights of ASH 2015
Generous Donations Help Fund 2016
Brian D. Novis Research Grants
MRD Testing in…
Resource
This comprehensive review provides a detailed analysis of the management of relapsed multiple myeloma (MM) based on the recommendations of the International Myeloma Working Group. It highlights the importance of managing relapsed MM, as nearly all patients eventually experience relapse despite…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Black Swan Research Initiative Update
Dr. Bruno Paiva Wins Bart Barlogie Young Investigator Award
African Americans and…
Resource
Managing the patient with multiple myeloma (MM) across the continuum of care is challenging given the heterogeneity of the population. Provided are IMF Patient Education Tools. These fact sheets discuss side effects that may result from the use of novel agents in multiple myeloma, and how to manage…
Resource
Written by the IMF Nurse Leadership Board, made up of experienced specialty oncology nurses, these are the first comprehensive guidelines for managing side effects from lenalidomide, thalidomide, and bortezomib used in the treatment of multiple myeloma. Published in the June 2008, Supplement to…
Resource
The International Myeloma Working Group has developed practical recommendations for the diagnosis and management of multiple myeloma-related renal impairment (RI). These recommendations are based on published data through December 2015 and were developed using the Grading of Recommendation,…
Resource
Dear Reader
A message from IMF President Susie Novis
Special Tribute
Michael S. Katz: Patient Advocate and Educator Extraordinaire
Scientific & Clinical
6th Annual International…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Myeloma Treament Progress Accelerates in US and Europe
IMF Chairs Tokyo Flow Workshop
Nurse Leadership Board…
Resource
This study aimed to assess the predictive role of a baseline geriatric assessment (GA) in elderly newly diagnosed multiple myeloma (MM) patients. A pooled analysis of 869 individual patient data from 3 prospective trials was conducted. The GA consisted of three tools: the Katz Activity of Daily…
Resource
This article presents the recommendations of the International Myeloma Working Group regarding the use of magnetic resonance imaging (MRI) in the management of multiple myeloma (MM). The aim of these recommendations is to provide practical guidance for the use of MRI in the diagnosis, staging,…
Resource
Dear Reader
A message from IMF President Susie Novis
Special Event
8th Annual Comedy Celebration
Scientific & Clinical
IMWG Issues New Guidelines for Early Diagnosis of…
Resource
The revised diagnostic criteria for multiple myeloma and smoldering multiple myeloma have been proposed by the International Myeloma Working Group. These criteria include specific requirements for bone marrow plasma cells, serum free light chain ratio, MRI findings, myeloma bone disease, renal…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
MRD Testing: Have We Found the Method We Need?
The Role of Salvage Transplant Therapy in Myeloma
Management of Side…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Key Questions 2014: Highlights from the 5th Annual IMWG Summit
Highlights from the 2014 Annual Meeting of…
Resource
Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow. Recent advancements in the understanding and management of MM have led to significant improvements in patient outcomes. The diagnosis of MM is based on the presence…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
SAR6500984: A New "Blockbuster" Drug For Myeloma
Black Swan Research Initiative® (BSRI®) Debut of a Highly Sensitive…
Resource
The current advancements in the treatment of multiple myeloma (MM) involve the use of various therapeutic agents, including immunomodulatory drugs (IMIDs), proteasome inhibitors (PIs), histone deacetylase (HDAC) inhibitors, and monoclonal antibodies (MoAbs). IMIDs such as thalidomide,…
Resource
Multiple myeloma (MM) is a heterogeneous disease with variable response to treatment and outcome. The International Myeloma Working Group (IMWG) has proposed a consensus on risk stratification in MM to better understand and apply treatment. Prognostic markers have been identified and…
Resource
This abstract provides a comprehensive overview of the management of multiple myeloma in patients who are not eligible for autologous stem-cell transplantation. It emphasizes the importance of early treatment initiation for patients with symptomatic disease and organ damage, such as hypercalcemia…
Resource
Dear Reader:
A message from IMF President Susie Novis
Scientific & Clinical:
Black Swan Research Initiative Moves Into High Gear
Highlights from the 2013 American Society of Hematology Annual…
Resource
Autologous hematopoietic stem cell transplantation (AHSCT) is an approved for the treatment for multiple myeloma. This article provides non-transplantation oncology nurses with guidelines for education, clinical management, and support of patients with multiple myeloma undergoing AHSCT. It provides…
Resource
This report compiles notes from roundtable meeting of members of the International Myeloma Foundation (IMF) Nurse Leadership Board who convened at the December 6th American Society of Hematology (ASH) Annual Meeting. They discussed treatment best practices for using VELCADE® in multiple myeloma (MM…
Resource
This document discusses the management of multiple myeloma in Asia, taking into account the resource limitations faced by developing countries in the region. The introduction of novel drugs has significantly improved survival outcomes for multiple myeloma patients, but the guidelines based on…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
IMWG Research Takes Center Stage at Stockholm Summit
Exciting months ahead for the IMF Black Swan Research Initiative
…
Resource
Dear Reader
The IMF convened the first-ever Global Leaders’ Summit in Stockholm, Sweden.
Scientific & Clinical
Dr. Kazuyuki Shimizu, president of the 14th International Myeloma Workshop (IMW…
Resource
Now more than ever before, multiple myeloma patients are assessed and treated more precisely. New technologies are now able to “evaluate the biology and extent of the disease,” including the following:
cytogenetic information
genetic abnormalities
extramedullary…
Resource
This study seeks to “assess the independent contributions of International Staging System (ISS) stage and cytogenetic abnormalities in predicting outcomes. This international effort used the International Myeloma Working Group database of 12,137 patients treated worldwide for myeloma at diagnosis,…
Resource
Dear Reader
2013! Sounds almost like something out of a science fiction novel. Yet it’ s our world today.
Scientific & Clinical
ASH 2012 – Summaries of Multiple Myeloma Presentations…
Resource
Dear Reader
A Message from the President
Special Event
Donor Appreciation Event
Scientific & Clinical…
Resource
Plasma cell leukemia (PCL), a rare and aggressive variant of myeloma, is characterized by the presence of circulating plasma cells. It is classified as either:
primary PCL occurring at diagnosis, or
secondary PCL in patients with relapsed/refractory myeloma.
…
Resource
This 2012 Myeloma Today, a multiple myeloma journal, is a Special Gala Report, covering the IMF’s 6th Annual Comedy Celebration.
Click here to download Myeloma Today
Resource
Dear Reader
A Message from the President
Special Event
Professor Jesús San-Miguel is recipient of the Tenth Robert A. Kyle Lifetime Achievement Award
Scientific & Clinical…
Resource
Dear Reader
Like Living with a Bad Neighbor
Scientific & Clinical
"Report from ASCO 2012: New Results in Frontline and at Relapse" by Dr. Brian Durie]
Supportive Care…
Resource
Peripheral neuropathy (PN), a complication of multiple myeloma (MM) treatment, can be caused by the myeloma itself, other aspects of the disease, or by its treatment. Such causes include
the effects of the monoclonal protein,
the results of radiculopathy from direct…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
"Best of ASH 2011 Recap: What Patients Need to Know" by Dr. Brian Durie
"2012 IMF Research Grants" by Dr. Robert Kyle
"Relapsed Multiple Myeloma After…
Resource
Many new drugs show promise in the treatment of multiple myeloma (MM); however, their “impact should be measured against the expected outcome in patients failing current therapies.” This study focused on “286 patients with relapsed MM, who were refractory to bortezomib and were relapsed following,…
Resource
It is important to maintain the results of induction therapy in multiple myeloma patients. The International Myeloma Working Group reviewed data associated with induction therapy.
Learn more about these induction treatments that were studied. The IMWG concluded that when deciding on treatment…
Resource
Dear Reader
A Message from the President
Scientific & Clinical:
Dr. Morton Coleman Shares an Overview of His 45-Year Career in MM
Dr. Noopur Raje…
Resource
This 2011 Myeloma Today, a multiple myeloma journal, is a Special Gala Report, covering the IMF’s 5th Annual Comedy Celebration.
Click here to download Myeloma Today